Insights on the association of anthropometric and metabolic variables with tumor features and genomic risk in luminal early breast cancer: Results of a multicentric prospective study

Pietro De Placido(University of Naples Federico II), Mario Giuliano(University of Naples Federico II), Margherita Tafuro(University of Naples Federico II), Bárbara Cardinali(Ospedale Policlinico San Martino), Claudio Vernieri(Fondazione IRCCS Istituto Nazionale dei Tumori), Aldo Caltavituro(University of Naples Federico II), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Carmine De Angelis(Baylor College of Medicine), Roberta Caputo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Grazia Arpino(University of Naples Federico II), Roberto Buonaiuto(University of Naples Federico II), Roberto Bianco(Federico II University Hospital), Claudia Martinelli(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Paola Di Rocco(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Vittoria D’Esposito(Institute for Experimental Endocrinology and Oncology), Pietro Formisano(Institute for Experimental Endocrinology and Oncology), Vincenzo Di Lauro(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Tommaso Ruelle(Ospedale Policlinico San Martino), Giuseppe Porciello(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Rossana Di Rienzo(University of Naples Federico II), Lucia Del Mastro(Ospedale Policlinico San Martino), Bianca Maria Veneziani(Federico II University Hospital), Erica Pietroluongo(University of Naples Federico II), Giuseppe Buono(Federico II University Hospital), Anna Crispo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Francesca Poggio(Ospedale Policlinico San Martino)
European Journal of Cancer
April 6, 2025
10.1016/j.ejca.2025.115409
Cited by 2

Related Papers

Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
|The Lancet|2007|912
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance
|Endocrine Reviews|2008|545